PEPG
PepGenCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The stock is depressed versus its prior biotech valuation range, the 5 mg/kg FREEDOM2 data were clean on safety, ex-U.S. enrollment/dosing continues despite the U.S.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -0.2.
What can break
10 mg/kg FREEDOM2 data may fail to show clearly improved splicing or functional benefit versus the 5 mg/kg cohort.
Momentum
33
Value
58
Sentiment
64
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.40 · Bull $3.40 · Bear $0.60
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $10.71
Why
Momentum33 · Δ7d -36.2
Value58 · Δ7d +0.1
Sentiment64 · Δ7d -0.2
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
33
34% active weight
Current posture
7d trendSoftening
Δ7d
-36.2
Δ21d
-58.2
Value
58
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.0
Sentiment
64
33% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-
Why this grade
Composite grade C. Momentum 33.0 / Value 57.7 / Sentiment 63.5
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$101.68M
Beta
1.92
Shares Out
68.75M
P/E (TTM) · Derived
-0.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.57
Rev YoY
-
EPS YoY
+20.1%
Gross Margin
-
Op Margin
-
Net Debt
-$120.19M
Current Ratio
13.15
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology